A comprehensive profile of TCF1⁺ progenitor and TCF1⁻ terminally exhausted PD-1⁺CD8⁺ T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy

Abstract

The heterogeneity of exhausted T cells (Tex) is a critical determinant of immune checkpoint blockade therapy efficacy. However, few studies have explored exhausted T cell subpopulations in human cancers. In the present study, we examined samples from two cohorts of 175 patients with head and neck squamous cell cancer (HNSCC) by multiplex immunohistochemistry (mIHC) to investigate two subsets of Tex, CD8⁺PD1⁺TCF1⁺ progenitor exhausted T cells (TCF1⁺Tex^prog) and CD8⁺PD1⁺TCF1⁻ terminally exhausted T cells (TCF1⁻Tex^term). Moreover, fresh tumor samples from 34 patients with HNSCC were examined by flow cytometry and immunohistochemistry to further investigate their properties and cytotoxic capabilities and their correlation with regulatory T cells (Tregs) in the tumor immune microenvironment (TIME). mIHC and flow cytometry analysis showed that TCF1⁻Tex^term represented a greater proportion of CD8⁺PD1⁺Tex than TCF1⁺Tex^prog in most patients. TCF1⁺Tex^prog produced abundant TNFα, while TCF1⁻Tex^term expressed higher levels of CD103, TIM-3, CTLA-4, and TIGIT. TCF1⁻Tex^term exhibited a polyfunctional TNFα⁺GZMB⁺IFNγ⁺ phenotype; and were associated with better overall survival and recurrence-free survival. The results also indicated that larger proportions of TCF1⁻Tex^term were accompanied by an increase in the proportion of Tregs. Therefore, it was concluded that TCF1⁻Tex^term was the major CD8⁺PD1⁺Tex subset in the HNSCC TIME and that these cells favor patient survival. A high proportion of TCF1⁻Tex^term was associated with greater Treg abundance.

References

[1] Ferris RL, . Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 2016, 375: 1856-1867.

[2] Massarelli E, . Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol., 2019, 5: 67-73.

[3] Kudo T, . Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol., 2017, 18: 631-639.

[4] Whiteside TL. Head and neck carcinoma immunotherapy: facts and hopes. Clin. Cancer Res., 2018, 24: 6-13.

[5] Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int. J. Oral. Sci., 2020, 12: 16.

[6] Blank CU, . Defining ‘T cell exhaustion’. Nat. Rev. Immunol., 2019, 19: 665-674.

[7] Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell, 2018, 33: 547-562.

[8] Miller BC, . Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol., 2019, 20: 326-336.

[9] Sade-Feldman M, . Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell, 2018, 175: 998-1013. e1020

[10] Siddiqui I, . Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity, 2019, 50: 195-211.

[11] Zeng Z, Wei F, Ren X. Exhausted T cells and epigenetic status. Cancer Biol. Med., 2020, 17: 923-936.

[12] Escobar, G., Mangani, D. & Anderson, A. C. T cell factor 1: a master regulator of the T cell response in disease. Sci. Immunol. https://doi.org/10.1126/sciimmunol.abb9726 (2020).

[13] Zhao, X., Shan, Q. & Xue, H. H. TCF1 in T cell immunity: a broadened frontier. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-021-00563-6 (2021).

[14] Wen S, . TCF-1 maintains CD8(+) T cell stemness in tumor microenvironment. J. Leukoc. Biol., 2021, 110: 585-590.

[15] Jansen CS, . An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature, 2019, 576: 465-470.

[16] Dammeijer F, . The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell, 2020, 38: 685-700.

[17] Nguyen N, . Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck, 2016, 38: 1074-1084.

[18] Fang J, . Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer, 2017, 17

[19] Balermpas P, . CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int. J. Cancer, 2016, 138: 171-181.

[20] Xiao Y, . CD103(+) T and dendritic cells indicate a favorable prognosis in oral cancer. J. Dent. Res., 2019, 98: 1480-1487.

[21] Hewavisenti, R. et al. CD103+ tumor-resident CD8+ T cell numbers underlie improved patient survival in oropharyngeal squamous cell carcinoma. J. Immunother. Cancer https://doi.org/10.1136/jitc-2019-000452 (2020).

[22] Ma J, . PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J. Immunother. Cancer, 2019, 7: 331.

[23] Kansy BA, . PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res., 2017, 77: 6353-6364.

[24] Liu X, . PD-1(+) TIGIT(+) CD8(+) T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunol. Immunother., 2019, 68: 2041-2054.

[25] Guo L, . Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer. Clin. Sci., 2020, 134: 711-726.

[26] Kaneko N, . Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell, 2020, 183: 143-157. e113

[27] Sharabi A, . Regulatory T cells in the treatment of disease. Nat. Rev. Drug Discov., 2018, 17: 823-844.

[28] Sawant DV, . Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion. Nat. Immunol., 2019, 20: 724-735.

[29] Beltra JC, . Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity, 2020, 52: 825-841.

[30] Shi M, Ye Z, Umeshappa KS, Moyana T, Xiang J. Alpha tumor necrosis factor contributes to CD8(+) T cell survival in the transition phase. Biochem. Biophys. Res. Commun., 2007, 360: 702-707.

[31] van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist, 2006, 11: 397-408.

[32] Held, W., Siddiqui, I., Schaeuble, K. & Speiser, D. E. Intratumoral CD8(+) T cells with stem cell-like properties: Implications for cancer immunotherapy. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aay6863 (2019).

[33] Baharom F, . Intravenous nanoparticle vaccination generates stem-like TCF1(+) neoantigen-specific CD8(+) T cells. Nat. Immunol., 2021, 22: 41-52.

[34] LaFleur MW, . PTPN2 regulates the generation of exhausted CD8(+) T cell subpopulations and restrains tumor immunity. Nat. Immunol., 2019, 20: 1335-1347.

[35] Seminerio, I. et al. Infiltration of FoxP3+ regulatory T cells is a strong and independent prognostic factor in head and neck squamous cell carcinoma. Cancers https://doi.org/10.3390/cancers11020227 (2019).

[36] Badoual C, . Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res., 2006, 12: 465-472.

[37] Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep., 2015, 5

[38] Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat. Rev. Immunol., 2017, 17: 703-717.

[39] van der Veeken J, . The transcription factor Foxp3 shapes regulatory T cell identity by tuning the activity of trans-acting intermediaries. Immunity, 2020, 53: 971-984. e975

[40] Liu JF, . Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J. Exp. Clin. Cancer Res., 2018, 37: 44.

[41] Song JJ, . Foxp3 overexpression in tumor cells predicts poor survival in oral squamous cell carcinoma. BMC Cancer, 2016, 16

[42] Li Q, . Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma. Int. J. Oral. Sci., 2020, 12: 24.

[43] Mao L, . gamma-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma. Int. J. Cancer, 2018, 142: 999-1009.

[44] Blenman KRM, Bosenberg MW. Immune cell and cell cluster phenotyping, quantitation, and visualization using in silico multiplexed images and tissue. Cytom. Cytom. A, 2019, 95: 399-410.

[45] Zhang SM, . KDM5B promtes immune evasion by recruiting SETDB1 to silence retroelements. Nature, 2021, 598: 682-687.

[46] Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics, 1992, 48: 73-85.

[47] Hothorn T, Lausen B. Maximally selected rank statistics in R. R. N., 2002, 2: 3-5.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81972532, 81772896, 81902778, 81500864, 81991500)